Our recent work discussed earlier has implicated the oncogenetic functions of SRD5A1 in CRC; thus, SRD5A1 inhibitors should be used to affirm the potential of SRD5A1 acting as a suitable therapeutic target in CRC. Here, SRD5A1 is linked to colorectal carcinoma.